Clinical Trials Using Paclitaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Paclitaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 177
< Previous 1 2 3 4 5 ... 8 Next >

  • Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients with HPV-Associated Oropharyngeal Squamous Cell Cancer

    This phase II trial studies how well chemotherapy and intensity-modulated radiation therapy work in treating patients with human papilloma virus (HPV)-associated oropharyngeal squamous cell cancer. Drugs used in chemotherapy, such as cisplatin, cetuximab, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving a lower dose of chemotherapy and radiation therapy may provide a similar cure rate as the longer, more intensive standard regimen.
    Location: 4 locations

  • Nivolumab with or without Relatlimab before Chemoradiotherapy in Treating Patients with Operable Stage II-III Esophageal or Gastroesophageal Junction Cancer

    This phase Ib trials studies the side effects of nivolumab with or without relatlimab before chemoradiotherapy in treating patients with stage II-III esophageal or gastroesophageal junction cancer that can be removed by surgery (operable). Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving nivolumab with or without relatlimab prior to current chemoradiotherapy works better in treating patients with esophageal or gastroesophageal junction cancer.
    Location: 4 locations

  • Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

    This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and / or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
    Location: 4 locations

  • Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer

    This phase Ib trial studies the side effects and best dose of taselisib when given with anti-human epidermal growth factor receptor 2 (HER2) therapies in treating patients with HER2 positive (HER2+) breast cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Taselisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as trastuzumab emtansine, pertuzumab, and trastuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Antihormone therapy, such as fulvestrant, may lessen the amount of estrogen made by the body. It is not yet known whether taselisib works better when given together with trastuzumab emtansine, pertuzumab, and trastuzumab, or with pertuzumab, trastuzumab, paclitaxel, and fulvestrant in treating patients with breast cancer.
    Location: 5 locations

  • Oxaliplatin, Leucovorin Calcium, and Fluorouracil Followed by Surgery and Response Based Concurrent Chemotherapy and Radiation Therapy in Treating Patients with Esophageal, Gastroesophageal Junction, or Gastric Cancer

    This phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil followed by surgery and response based concurrent chemotherapy and radiation therapy works in treating patients with esophageal, gastroesophageal junction, or gastric cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving chemotherapy followed by surgery and response based chemotherapy and radiation therapy may kill more tumor cells.
    Location: 4 locations

  • Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Breast Cancer

    This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer. Drugs used in chemotherapy, such as paclitaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, may block tumor growth in different ways by targeting certain cells. Giving combination chemotherapy with or without trastuzumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: 4 locations

  • A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer

    This is a Phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced (Stage III or IV) endometrial cancer.
    Location: 10 locations

  • Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC)

    This phase II trial studies how well MLN4924 (pevonedistat), carboplatin, and paclitaxel work in treating patients with stage IIIB or IV non-small cell lung cancer. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pevonedistat together with carboplatin and paclitaxel may work better in treating patients with non-small cell lung cancer when compared with other standard chemotherapy drugs.
    Location: 3 locations

  • A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

    This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).
    Location: 3 locations

  • A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline / Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

    This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
    Location: 3 locations

  • Trastuzumab, Pertuzumab, and Combination Chemotherapy in Treating Patients with Locally Advanced, Resectable, or Inflammatory Her2 Positive Breast Cancer

    This phase II trial studies how well two different anti-cancer treatment regimens which both contain trastuzumab and pertuzumab, but with different combinations of chemotherapy work in shrinking cancer before surgery in patients with localized Her2 positive breast cancer. Trastuzumab and pertuzumab are forms of “targeted therapy” because they work by attaching to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab or pertuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, paclitaxel, docetaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab with pertuzumab, in addition to combination chemotherapy has been shown to be very effective in shrinking cancer before surgery in patients with Her2 positive locally advanced breast cancer. This trial aims to help determine which regimen may work best with the least toxicity.
    Location: 3 locations

  • FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients with HER2 Positive Advanced Breast Cancer

    This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as trastuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FASN inhibitor TVB-2640, paclitaxel, and trastuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: 3 locations

  • Pembrolizumab with or without Paclitaxel or Irinotecan in Treating Patients with Locally Advanced or Metastatic High Grade Neuroendocrine Cancer

    This phase II clinical trial studies how well pembrolizumab with or without paclitaxel or irinotecan works in treating patients with high grade neuroendocrine cancer that has spread to nearby tissues or lymph nodes or other places in the body. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without paclitaxel or irinotecan hydrochloride may work better in treating patients with neuroendocrine cancer.
    Location: 3 locations

  • Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor, has spread to other places in the body, or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as atezolizumab, trastuzumab, and pertuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: 3 locations

  • Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients with Stage I-II HER2 / neu Positive Breast Cancer after Surgery

    This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2 / neu) positive breast cancer (confined to the breast or the breast and lymph nodes under the arm). Drugs used in chemotherapy, such as cyclophosphamide and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving cyclophosphamide, paclitaxel, and trastuzumab after surgery may help prevent the cancer from coming back.
    Location: 3 locations

  • Phase 1 / 2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

    This trial is a Phase 1b / 2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy concurrently and continued as a maintenance therapy for up to 12 months.
    Location: 3 locations

  • MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer

    This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.
    Location: 3 locations

  • Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs. Drugs used in chemotherapy, such as paclitaxel, gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Using an Avatar, a living tumor sample with similar genetic characteristics to the original tumor, may help determine which chemotherapy is most effective.
    Location: 3 locations

  • Surgery and Chemotherapy with or without Chemotherapy after Surgery in Treating Patients with Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

    This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal cancer. Giving a dose of heated chemotherapy into the abdomen during surgery that is done to remove ovarian, fallopian tube, uterine, or peritoneal cancer may help lower the risk of the cancer coming back. Giving unheated chemotherapy drugs directly into the abdomen after surgery may kill more tumor cells.
    Location: 4 locations

  • A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008 / KEYLYNK-008)

    The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to overall survival (OS).
    Location: 3 locations

  • M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

    The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
    Location: 5 locations

  • A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

    The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in patients with advanced unresectable / metastatic ESCC.
    Location: 2 locations

  • Nivolumab and Standard Chemotherapy before Surgery in Treating Patients with Inflammatory Breast Cancer

    This phase II trial studies how well nivolumab and standard chemotherapy work before surgery in treating patients with inflammatory breast cancer. Immunotherapy with a monoclonal antibody such as nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a protein that is present on different types of cells in the immune system and controls parts of the immune system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from shutting down the immune system, thus allowing immune cells to recognize and destroy tumor cells. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to determine whether the addition of nivolumab to standard chemotherapy improves response rate in patients with inflammatory breast cancer.
    Location: 2 locations

  • Radiation Therapy, Chemotherapy, Ipilimumab, and Nivolumab in Treating Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

    This phase I / II trial studies the side effects and how well ipilimumab with radiation therapy and chemotherapy followed by nivolumab works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, carboplatin, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ipilimumab with radiation therapy and chemotherapy followed by nivolumab may work better in treating patients with non-small cell lung cancer.
    Location: 2 locations

  • A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and / or Refractory Solid Tumors

    An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), subjects will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), subjects will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll subjects with relapsed or refractory (R / R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll subjects with R / R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
    Location: 5 locations


< Previous 1 2 3 4 5 ... 8 Next >